A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
commercialization with strong product
lifecycle management capability
Focusing on our advantageous specialty areas, targeting unmet clinical needs, we continuously identify and develop first-in-class (FIC) and best-in-class (BIC) innovative products.
Upholding clinical value as the core, we deliver competitive products and services that enhance disease diagnosis and treatment as well as clinical practice, ultimately benefiting patients.
Desidustat Tablets are a noveloral HIF-PHI, approved for treating anaemia in non-dialysis adult CKD patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia. The China Phase III clinical trial of the Product has demonstrated positive results: the study met its primary efficacy endpoint. Extension study results demonstrated that the Product can maintain Hb level within the target range over the long term with acceptable safety, while significantly reducing hepcidin levels and amelioratingiron metabolism disorders. The Product will strengthen the Group’s layout in the field of nephrology and synergize with the marketed innovative drug Velphoro for CKD hyperphosphatemia in terms of expert resources and channel networks. China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved […]
We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.
If you are interested in joining us, or curious about our business and products, please feel free to contact us.